Dec 16, 2021 6:30am EST Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Fourth and Final Cohort of Patients in the EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis
Nov 18, 2021 7:00am EST Matinas BioPharma to Participate in 33rd Annual Piper Sandler Virtual Healthcare Conference
Nov 08, 2021 6:35am EST Matinas BioPharma Reports Third Quarter 2021 Financial Results and Operational Highlights
Nov 02, 2021 7:00am EDT Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2021 Financial and Operational Results on November 8, 2021
Oct 25, 2021 7:00am EDT Matinas BioPharma Selected to Participate in the B. Riley Fall 2021 Growth Biotech Best Ideas Series
Oct 21, 2021 7:00am EDT Matinas BioPharma Initiates Dosing in Phase 1 Study of Potential First Oral Aminoglycoside Antibiotic Drug MAT2501
Sep 20, 2021 7:00am EDT Matinas BioPharma Announces Accomplished Biotechnology Executive and Drug Developer Kathryn Penkus Corzo as Nominee to the Board of Directors
Sep 14, 2021 7:00am EDT Matinas BioPharma Announces Webcast of Presentation at the H.C. Wainwright Global Investment Conference
Sep 13, 2021 6:00am EDT Matinas BioPharma Announces Positive Data in the Ongoing EnACT Trial of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis, Exceeding the Prespecified Primary Endpoint Threshold
